Navigation Links
NxStage Medical to Present at William Blair Growth Stock Conference
Date:6/5/2008

LAWRENCE, Mass., June 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Robert S. Brown, Chief Financial Officer, will be presenting at the William Blair 28th Annual Growth Stock Conference on June 18, 2008 at the Four Seasons Hotel in Chicago, Ill.

NxStage's investor presentation is scheduled for Wednesday, June 18th at 3:10 p.m. CT. To listen to the audio webcast of the presentation during the event, please visit: http://www.nxstage.com and click on 'Investor Information.' A replay will be available for 30 days immediately following the live presentation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Mr. Burbank's and Mr. Brown's plans to present at the William Blair Growth Stock Conference. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:

Kristen K. Sheppard, Esq.

Investor Relations

ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
2. NxStage Medical Announces Needle Supply Agreement with DaVita
3. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
4. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
5. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
6. NxStage Medical Provides Update on Medisystems Acquisition
7. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
8. Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference
9. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
10. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
11. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading provider of ... that it has been named to The Silicon Review’s “20 Fastest Growing Big Data ... Cambridge Semantics serves the needs of end users facing some of the most complex ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was ... since 1987. Since then, he has served in a number of key leadership positions ... the program and exposition committees. In his professional career, Dr. Gardner is the director ...
(Date:4/27/2016)... 27, 2016 NanoStruck Technologies ... NSKQB) ( Frankfurt : 8NSK) gibt ... vom 13. August 2015 die Genehmigung von der ... zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, ... Davon wurden 157.900.000 Einheiten mit dem ersten Teil ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board ... the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven ... the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):